Skip to content

The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers

The Effects of Resveratrol on Inhibitors of Apoptosis Proteins, on Soluble Receptors of Advanced Glycation End Products and on Sirtuins-1 and -3 in Postmenopausal Women With Coronary Artery Disease

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05808387
Acronym
RE-AGES
Enrollment
80
Registered
2023-04-11
Start date
2023-03-06
Completion date
2026-06-05
Last updated
2023-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Endothelial Dysfunction, Menopause

Keywords

Coronary artery disease, Menopause, Endothelial Dysfunction, Sirtuin, Receptors of advanced glycation end products, Apoptosis, Resveratrol, Polyphenols, Cardiovascular risk

Brief summary

Cardiovascular diseases (CVD) and neoplasms are the main causes of death in Brazilian women. Coronary artery disease (CAD) and stroke were responsible for approximately 54% of deaths from CVD in this population. In Brazil, cancers were the second cause of death and in 2017 were responsible for 58% of deaths in women. CVD and cancer share some risk factors, and control of these factors is associated with a significant reduction in cancer incidence. These two causes of death, although apparently disparate, share similar lifestyles and health risk factors, suggesting some common pathways and basic molecular networks. In women, the presence of estrogen has protective effects against atherosclerosis and, with the decline in hormone production at menopause, the incidence and prevalence of CAD increase substantially. Although the estrogen pathway is supposed to have a central effect on this increased risk, it is still debated whether other non-estrogenic mechanisms are related, since hormone replacement alone does not reduce cardiovascular events. Sirtuins and soluble advanced glycation product receptors (sRAGE) are associated with increased vascular protection, while the role of apoptosis inhibiting proteins, a pathway linked to increased cancer incidence, is still unclear in the context of atherosclerosis. Resveratrol is a key activator of sirtuins and potentially modulates these metabolic pathways, reducing cardiovascular risk. This randomized, double-blind, parallel, placebo-controlled clinical trial will be carried out in 80 postmenopausal women with CAD to analyze the effect of treatment with resveratrol on serum concentration and gene expression of sirtuins-1 -3, in the serum sRAGE concentration and in the gene expression of apoptosis inhibitory proteins.

Detailed description

The objective of the study is to evaluate the influence of sirtuins stimulation by resveratrol on inhibitors of apoptosis proteins gene expression of circulation angiogenic cells of postmenopausal women with stable coronary artery disease. A randomized, double-blind, parallel, placebo-controlled clinical trial in postmenopausal women with CAD submitted to 90 days of daily resveratrol supplementation days of daily supplementation with 1000 mg of resveratrol. Eighty women aged ≥55 years, with overweight or obesity grade 1 (BMI between 25 and 35 kg/m2) will be selected. The participants will be randomized into two groups, control (CON) and resveratrol (RES). After the screening, the participants will undergo the first clinical and laboratory evaluation including lipid and glucose metabolism, inflammatory biomarkers, serum concentrations and gene expression of sirtuin-1 and sirtuin-3 and soluble receptor of advanced glycation end products, and the gene expression of inhibitors of apoptosis proteins.

Interventions

DIETARY_SUPPLEMENTResveratrol

Trans-resveratrol, 1000 mg daily for 90 days

DIETARY_SUPPLEMENTPlacebo

Starch, 1000 mg daily for 90 days

Sponsors

InCor Heart Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

Participants in the control group will receive capsules identical to those in the intervention group, but with cornstarch. The care provider and the participants do not have the information about which capsules the participant is taking, and do not have access to which groups the patients belong. Statistical analyses will be performed on a blinded database, i.e. without information of which groups the participants belong to. Only the principal investigator of the study has this information.

Intervention model description

Double blind randomized controlled trial, parallel and placebo-controlled.

Eligibility

Sex/Gender
FEMALE
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Postmenopausal women; * Diagnosed coronary artery disease; * Stable coronary disease;

Exclusion criteria

* hypo or hyperthyroidism, * rheumatic disease, * use of alcohol, * hepatic failure, * renal failure * hormone replacement therapy * use of insulin

Design outcomes

Primary

MeasureTime frameDescription
Sirtuin-1 and sirtuin-390 daysSerum concentrations and gene expression
Inhibitors of apoptosis proteins90 daysGene expression of Bcl-2, XIAP, c-IAP1, and survivin
sRAGE90 daysSerum concentrations and gene expression

Secondary

MeasureTime frameDescription
Inflammation90 daysSerum concentrations of proinflammatory cytokines
Cardiometabolic risk factors90 daysLipid and glucometabolic profiles
Anthropometric measures90 daysBMI, skinfold thickness, and body composition

Countries

Brazil

Contacts

Primary ContactAntonio P Mansur, PhD
apmansur@yahoo.com551126615448

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026